Pheochromocytoma: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Pheochromocytoma is a catecholamine-secreting neuroendocrine tumor arising from chromaffin cells of the adrenal medulla. It is a rare but potentially life-threatening condition, with an estimated incidence of approximately 2-8 cases per million population per year in the United States, though the true incidence is higher due to incidental detection on cross-sectional imaging. Pheochromocytomas have historically been associated with the 'rule of tens' — approximately 10% bilateral, 10% extraadrenal (the correct term for which is paraganglioma), 10% malignant, and 10% hereditary — though more contemporary data show that up to 40% have a hereditary basis. Malignancy (defined by the presence of metastases at sites where chromaffin tissue does not normally reside) occurs in approximately 10-15% of cases and is significantly associated with SDHB germline mutations. The disease is classically referred to as the 'great mimicker' because its paroxysmal catecholamine-driven symptoms can simulate hypertensive emergencies, panic disorder, and numerous other conditions.

Approximately 40% of pheochromocytomas arise in the context of a germline mutation in one of over 15 identified susceptibility genes. The most clinically important hereditary syndromes include: VHL syndrome (von Hippel-Lindau disease, VHL gene mutation) — associated with predominantly norepinephrine-secreting bilateral pheochromocytomas combined with hemangioblastomas, clear cell RCC, and pancreatic neuroendocrine tumors; multiple endocrine neoplasia type 2A and 2B (MEN2, RET gene mutations) — associated with bilateral pheochromocytomas combined with medullary thyroid carcinoma and primary hyperparathyroidism; neurofibromatosis type 1 (NF1 gene) — associated with elevated pheochromocytoma risk in a minority of patients; and SDH subunit gene mutations (SDHB, SDHC, SDHD) — SDHB mutations most strongly predispose to malignant behavior (approximately 30-50% malignancy rate). Somatic mutations in VHL, RET, EPAS1, and MAX drive the majority of sporadic non-hereditary cases. Somatic EPAS1 (HIF2A) gain-of-function mutations cause polycythemia-paraganglioma-pheochromocytoma syndrome.

The classic symptom triad of pheochromocytoma is episodic or sustained hypertension combined with pounding headache, profuse diaphoresis (sweating), and palpitations — occurring in paroxysms lasting minutes to hours. Additional catecholamine-excess manifestations include pallor (rather than flushing), anxiety, sense of impending doom, tremor, hyperglycemia, weight loss, and heat intolerance. Paroxysms may be spontaneous or precipitated by postural changes, physical exertion, palpation of the tumor, certain foods (tyramine-containing foods), anesthesia induction, or medications including metoclopramide, tricyclic antidepressants, glucagon, and opioids. Hypertensive crisis precipitated by unrecognized pheochromocytoma during unrelated surgery is a classic and potentially fatal scenario. Approximately 10-15% of cases are normotensive (particularly dopamine-secreting tumors), and some are entirely asymptomatic, discovered as adrenal incidentalomas on imaging performed for unrelated indications. Bilateral disease (as in VHL, MEN2) may produce more complex endocrine manifestations.

Biochemical diagnosis is established by measuring plasma fractionated free metanephrines (sensitivity greater than 96%, first-line test) or 24-hour urine fractionated metanephrines and catecholamines. Values greater than three times the upper limit of normal are highly specific for pheochromocytoma. Confirmatory anatomic localization uses CT (with or without adrenal protocol: unenhanced Hounsfield units, washout characteristics) or MRI of the adrenal glands. Functional imaging with 123I-MIBG scintigraphy or 68Ga-DOTATATE PET/CT identifies multifocal or metastatic disease and is essential for patients being considered for MIBG therapy. Germline genetic testing (full SDH subunit panel, VHL, RET, NF1, MAX, TMEM127, EPAS1) is recommended for all patients with pheochromocytoma regardless of age, clinical presentation, or family history, per Endocrine Society guidelines.

Surgical resection is the curative treatment for localized pheochromocytoma. Mandatory pre-operative medical preparation for all functional tumors begins 10-14 days before surgery with phenoxybenzamine (non-selective irreversible alpha-adrenergic blocker, starting at 10 mg twice daily and titrating upward), which prevents the catastrophic catecholamine surge during tumor manipulation. Doxazosin (selective alpha-1 blocker) is an alternative at some centers. Beta-adrenergic blockade (propranolol or atenolol) is added only after adequate alpha-blockade has been achieved, to control reflex tachycardia — using beta-blockers before alpha-blockade can precipitate hypertensive crisis by leaving unopposed alpha-receptor stimulation. Salt and fluid loading prevents the post-resection hypotension that occurs as vascular tone normalizes. Laparoscopic adrenalectomy (transabdominal or retroperitoneoscopic approach) is the standard surgical technique for most tumors less than 6-8 cm without local invasion. Open adrenalectomy is used for large, complex, or locally invasive tumors. For metastatic pheochromocytoma: 131I-MIBG therapy (including high-activity Azedra formulation) for MIBG-avid disease; 177Lu-DOTATATE PRRT for DOTATATE-avid disease; sunitinib, cabozantinib, or temozolomide-based regimens for refractory cases.

No primary preventive measures exist for sporadic pheochromocytoma. However, systematic genetic surveillance of hereditary syndrome carriers enables detection at an earlier and more curable stage. VHL syndrome patients should undergo annual plasma or urine metanephrine measurement and abdominal MRI or ultrasound starting at age 5. MEN2A and MEN2B patients should undergo annual biochemical screening from the time of RET mutation detection. SDHB and SDHD carriers require lifelong biochemical and imaging surveillance every 1-2 years. All first-degree relatives of patients with confirmed germline pheochromocytoma-predisposing mutations should receive genetic counseling and cascade testing. Patients with known VHL or MEN2 syndromes should be managed at centers with endocrine oncology expertise where multidisciplinary surveillance is coordinated. Avoidance of medications that can trigger catecholamine release (metoclopramide, glucagon, contrast agents, opioids) is important in patients with known or suspected functional tumors.

Any patient with episodic spells of severe headache, profuse sweating, palpitations, and notable blood pressure elevation — particularly when these symptoms occur in paroxysms lasting minutes — should be evaluated urgently for pheochromocytoma. These spells may be infrequent and brief, and are often initially attributed to anxiety, panic attacks, or essential hypertension. Hypertension that is resistant to multiple antihypertensive agents in a young patient, or that is paroxysmal and episodic, requires an endocrinologist evaluation with biochemical exclusion of pheochromocytoma. An incidentally discovered adrenal mass on CT or MRI performed for any reason — even in the absence of classic symptoms — requires biochemical evaluation to exclude pheochromocytoma before any intervention is planned. Patients with VHL, MEN2, NF1, or a known SDHB/SDHD mutation who develop new hypertensive symptoms, palpitations, or headaches should be evaluated immediately. Pheochromocytoma must be biochemically excluded before adrenal surgery for any indication.

Complete laparoscopic adrenalectomy achieves biochemical cure in over 95% of benign cases. Annual biochemical surveillance is essential for life, as late recurrence is recognized. Malignant (metastatic) pheochromocytoma: 5-year survival approximately 36-60%, varying with SDHB mutation status, disease extent, and MIBG/DOTATATE avidity for targeted radionuclide therapy. The prognosis for Pheochromocytoma: Causes, Symptoms, Diagnosis and Treatment varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.